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DECISION-CTO:  
A “negative” clinical trial? Really?
Last March the re-
sults of the DECISION-
-CTO randomised trial 
were finally presented 
during the ACC Congress 
in Washington. This is 
a long-awaited paramount 
piece of evidence, be-
cause it is the largest 
randomised clinical trial 
comparing a strategy of 
percutaneous revascu-
larisation in chronic total occlusions (CTO) vs. 
optimal medical treatment (OMT) hitherto. The 
trial however failed to show any significant differ-
ence in the primary composite endpoint (mortality 
of any cause, non-fatal myocardial infarction [MI] 
and any revascularisation) at 3-years follow-up, 
so it has been presented as a “negative” trial for 
percutaneous coronary intervention (PCI) in this 
challenging scenario, or in a more positive formula-
tion, as “non-inferiority” of OMT vs. PCI. 
It is somewhat surprising the general defeat-
ism that has pervaded the interventional com-
munity after these apparently disappointing re-
sults, even among CTO-experts. Uncountable 
press-releases highlight a discouraging message, 
with striking words like “negative”, “fails”, “non-
significant”, etc. Key opinion leaders surrendered 
to the general panic and tried to find refuge in 
polyvalent commonplaces, like the need to select 
better the patients, the indisputable benefit of  an 
interventional approach in some cases after their 
personal experience, or the geographical frame of 
the study, that rather sounded like an attempt to 
save some personal belongings from the anticipated 
tsunami. These remarks implicitly accept and 
convey a negative result from the trial. Only my 
dear friend Davide Capodanno in his PCR news 
was cautious enough as to interpret the trial as 
negative, but concluding that the result leaves 
the question about the benefits of PCI in CTOs 
essentially unanswered.
Is DECISION-CTO a negative trial indeed? 
Formally it is so, no question, because it has failed 
to prove superiority in 
the predefined primary 
endpoint. For those who 
like to interpret the clin-
ical trials in simplistic 
soccer terms, this will 
ever remain the devas-
tating summary of such 
a precious collection of 
data: PCI 1 – OMT 1, tie, 
therefore the safest and 
cheapest option, namely 
OMT, prevails. This might be a good approach for 
soccer, maybe also for clinical routine, since we 
are often confronted with decisions that appear as 
a sharp dichotomy without nuances. Nonetheless, 
before accepting the defeat of PCI, it might be 
worth analysing the data with some deeper detail.
 — The estimated sample size was 1284, however 
the trial was prematurely stopped due to dif-
ficulties to enrol patients. The final number of 
patients included was 834. Moreover, most of 
patients came from a single centre, very active 
in the recruitment.
 — The cross-over was not negligible: 72 patients 
in the OMT arm (18.1%) underwent PCI, 
whilst 65 patients in the PCI arm (15.6%) 
were treated with OMT (36 of them due to 
failed PCI).
 — Peri-procedural MI, defined as an increase x5 
in the levels of cardiac markers, was included 
as part of the primary endpoint. Actually the 
differences in non-fatal MI were exclusively 
due to the differences in periprocedural MI, 
but there were no differences in spontaneous 
MI along the reported 5 years follow-up.
 — PCI was penalised with more non-fatal MIs 
(namely periprocedural) and revascularisa-
tions, nonetheless the overall mortality in the 
PCI arm was sensibly lower than in the OMT 
arm (3.0% vs. 4.4% at 3y follow-up, and 4.5% 
vs. 7.9% at 5y follow-up), with a reduction of 
50% in the particular case of cardiac death at 
the 3rd year (1.9% vs. 3.6%). Of course these 
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number at risk is as low as 409 at 3 years and 
just 155 at the 5th year. This means that the 
follow-up is still incomplete in many cases or 
that the study was undermined by unaccepta-
ble loss at follow-up.
 — The incidence of stroke was 5-fold higher in 
the OMT group (5% vs. 1%) at 5 years, close 
to reach statistical significance, although the 
patients at risk at that point were only 151.
 — In the per-protocol and as-treated analysis, 
PCI was superior to OMT, so the latter failed 
to prove non-inferiority. The superiority of 
PCI for the composite endpoint was close to 
reach statistical significance, even though the 
patients at risk were only 353 at the 3rd year 
of follow up and 137 at the 5th year.
In light of the above, I perceive DECISION-
-CTO as an utmost encouraging trial, close to prove 
the clinical advantages of an interventional strategy 
in patients with a CTO. I see no “negative trial” 
at all, but maybe this is just because I am not so 
much into soccer. 
As statistician I see just an underpowered 
trial with problems in its design and execution. It 
was clearly a mistake in the design including the 
peri-procedural MI, because it burdens consider-
ably the PCI arm. Such complex interventions are 
almost systematically associated with an increase 
in cardiac markers due to the technique (occlusion 
of small side branches, subintimal courses, stenting 
of long segments, transient occlusion of the collater-
als, reversal of the collateral flow, etc.), in most of 
cases without any clinical consequence at all. The 
highest increases in cardiac markers happen in the 
CTOs with the largest myocardium in jeopardy, cor-
responding paradoxically to the patients who benefit 
the most from the intervention. Most interestingly, 
the data obtained allow us to calculate quite pre-
cisely the required sample size to demonstrate a net 
benefit in a major endpoint like mortality.
 — If the primary endpoint had been all-cause 
mortality at 5 years, in the intention-to-treat 
analysis, a sample size of 1696 patients 
would have resulted in a statistically sig-
nificant difference. The completion of the 
initially-planned sample size would still remain 
non-significant, but just an increase in 32% 
would have rendered a statistically significant 
difference: PCI 1 – OMT 0, for our soccer fans. 
In that scenario, it is important to notice that 
the number-needed-to-treat is just 29 patients, 
i.e. we need to perform just 29 CTO-PCIs 
to spare one live at 5 years follow-up.
 — The cross-over introduced too much noise as 
to draw a too assertive conclusion. Actually in 
the as-treated analysis, OMT failed to appear 
as non-inferior to PCI, because PCI performed 
clearly better in the composite endpoint. 
If there had been no cross-over, a sam-
ple size of 1282 would have resulted in 
a statistically significant difference fa-
vouring PCI. Actually this is quite precisely 
the estimated sample size of the investigators, 
that must be congratulated for their excellent 
job. It was just the cross-over, impossible to 
anticipate in such complex trials, the factor 
that somehow ruined their accurate calcula-
tion. In this scenario, the number-needed-to-
-treat (NNT) is just 15 patients, i.e. we need 
to treat SUCCESFULLY just 15 CTOs 
to spare one life, MI, stroke or to avoid 
a revascularisation at 5 years follow-up. 
Similar results, for the same endpoint at 
3 years follow-up, with a NNT = 18 patients.
 — The differences in stroke will become sta-
tistically significant when the follow-up is 
completed in all patients, if the current trend 
is maintained (only 670 are required for that), 
favouring the PCI.
As interventional cardiologist, the trial offers 
lots of fascinating pearls that confirm or challenge 
my current perception about CTO-PCI. I am not 
truly surprised for the benefit in mortality, because 
it confirms somehow the data reported in previous 
observational or post-hoc studies [1–6]. I find also 
clinically unacceptable stating that a treatment is 
non-inferior to another one, based on a composite 
endpoint, when its different components move 
clearly in different directions for each therapeutic 
option. This is acceptable if all the components of 
the endpoint move consistently in the same direc-
tion, but it makes absolutely no sense trading off 
lives or strokes (where PCI performs better) for 
troponins and recaths (where OMT performs bet-
ter). As physician or as patient I would not hesitate. 
Furthermore, OMT is clearly inferior to PCI in 
the per-protocol or in the as-treated analysis, very 
close to reach statistical significance, as we have 
already discussed. Therefore, we just need to offer 
our patients a successful revascularisation. We do 
not need to select the patients better, we need 
to select the operators better.
I find also very interesting noticing that the 
success rate was as high as 91.1% and that ret-
rograde approaches were used in 24.6% of cases, 
because this speaks in favour of the quality of the 
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operators and of the interventions performed, cor-
responding to a modern, professional and dedicated 
CTO-program. Still the use of IVUS was only 6%, 
even though it can be instrumental in complex 
CTO-interventions.
Finally, some data are intriguing. Excitingly 
intriguing is the observation that the subgroup 
which seems to benefit the most from the PCI is 
that of the patients without angina. This challenges 
definitely the common established perception. 
Disappointingly intriguing is the observation that 
PCI does not improve the quality of life or the 
frequency of angina, because it is at variance with 
my daily experience treating patients with CTOs. 
These data will require further elaboration and 
need to be confirmed in future studies.
In summary, perhaps DECISION-CTO might 
have failed to reach its predefined endpoints, but 
has provided us with the information necessary to 
prove the clinical benefit of PCI in CTO in a future 
trial. Therefore, I perceive DECISION-CTO as 
a positive and encouraging trial: the investigators 
must be congratulated for an excellent job. They 
have taught us a lot of lessons that must be learned 
in the planning of subsequent studies. We can-
not underestimate the logistic problems, like the 
limited number of operators able to warrant an ac-
ceptable success rate, the difficulties to recruit and 
randomise patients, the unavoidable cross-over, 
etc. Still we must find the way to surmount all these 
limitations, because soccer is most popular in our 
society, including cardiologist, so it is mandatory 
to design a match in which PCI can win. Otherwise 
we will not convince our sceptical soccer-fan col-
leges, no matter how thoughtful considerations 
we present them.
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